Spero Therapeutics (NASDAQ:SPRO) was upgraded by analysts at
Wall Street
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)